Project Grant 2321926
Award Date
3/1/24
Completion Date
2/28/25
Dollars Obligated
$275K
Federal Agency
National Science Foundation
Awardee
Covalabio Inc. (WQNNR7LE5Y99)
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Getzville, NY 14068, USA
Similar Awards
This $275,000 National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award aims to develop a novel method for turning on cancer immunotherapies only at the site of disease. The goal is to create safer and more effective cancer treatments by engineering protein therapeutics that can sense and respond to disease-specific signals, avoiding off-target effects and toxicity. The funding supports proof-of-concept research by Synsorybio, Inc., a...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 provides funding to Tectaria Bio LLC to test the feasibility and application of a novel technology to significantly increase the protein production capabilities of cell lines used in the manufacture of biologics, gene therapies, and vaccines. The overarching goal is to reduce the costs associated with the biomanufacture of advanced therapies by improving the efficiency...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant for $275,000 awarded to Foragr Medicines, Inc. on January 15, 2025 will support the development of a high-throughput platform for small molecule, in-cell targeting of undruggable proteins via their mRNAs.
The goal is to create an efficient and cost-effective approach for developing therapeutics for previously undruggable diseases, including hard to treat neurodegenerative diseases and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Cerflux Inc. aims to develop a personalized cancer treatment screening platform. The project will establish guidelines for handling solid tumor biopsy samples, generate 3D bioprinted tumor models for validation, and demonstrate the platform's ability to match patients with the most effective cancer treatments before treatment begins. This innovative approach has the...
This Project Grant awarded by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC to develop a combinatorial high-throughput screening platform for generating improved molecular recognition components for use in therapeutic and diagnostic antibodies. The core aim is to creatively and efficiently use genetic information from patients, pathogens, and antibodies to advance therapeutics and...
This $274,594 Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports research and development of an innovative technology for cancer diagnosis and treatment. The project aims to improve molecular profiling and clinical laboratory testing of cancer samples by optimizing microdissection techniques. The research will focus on modeling and optimizing the opto-thermal-mechanical interactions involved in microdissection...
This National Science Foundation Project Grant of $255,995 supported Encapsulate Inc. to develop an automated biochip platform for personalized cancer screening under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084). The award period was from May 15, 2022 to April 30, 2023.
The platform will grow patient-derived cancer cells outside the body on biochips to screen them against chemotherapy drugs. This addresses the problem that over 70% of cancer patients undergo...
This SBIR Phase I Project Grant from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $274,991 to Saber Therapeutics, Inc. to develop a novel approach for delivering cancer-killing protein therapeutics specifically to acute myeloid leukemia (AML) cells. The project aims to create engineered natural killer (NK) cells equipped with targeted protein degraders (TPDs) that can selectively eliminate AML cells while sparing healthy...
This $305,000 federal Project Grant award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel mammalian cell-based nano-biological coating for implantable medical devices. The primary objectives are to: (1) characterize the nanoparticles produced by different cells on orthopedic implant materials, (2) determine the antibacterial, anti-inflammatory, and cell proliferation properties of the coated...
This $999,998 Cooperative Agreement award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel bioprocessing system to isolate and purify therapeutic antibodies directly from cell culture. The project aims to simplify the purification of biologics, reduce manufacturing costs, and improve product quality compared to current technologies. Key goals include scaling up the proprietary nanoparticle-based...